Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
PI3K Inhibitors Are Highly Active in R/R Follicular Lymphoma, New Dosing Strategies May Improve Tolerance Without Sacrificing Efficacy
Login to view comments.
Click here to Login
Malignant Hematology